International (ICH regions and adopting regulators)

ICH E6(R3)

64 controls. 109 other frameworks in our corpus share controls with it. Here is all of it, and how much of it you are already doing.

Page built . This page is derived from the framework corpus, which changes when the corpus is extended rather than daily.

64 controls 109 frameworks share controls with it International (ICH regions and adopting regulators) verified against its source document

Every control below is one this framework asks for. The right hand column counts how many other frameworks in our corpus carry the same control, which is the difference between doing this work once and doing it again for the next standard.

There is no implementation kit for this framework yet. The control list and the overlap above are free and complete.

What you already have

Frameworks whose controls overlap this one, most first. If you run any of them, the count is roughly what you have already evidenced.

Every control

CodeControlAlso in
ICH-E6-Annex1-ElectronicSystems-CSV-eSig-Audit-ALCOA-DataIntegrityICH E6(R3) Annex 1 - Computer Systems + Computer System Validation (CSV) + Electronic Signature + Audit Trail + ALCOA+ Data Integrity55
ICH-E6-Annex2-DecentralisedClinicalTrials-DCT-eConsent-Remote-WearablesICH E6(R3) Annex 2 - Decentralised Clinical Trial (DCT) Elements + eConsent + Remote Monitoring + Wearables + Real-World Evidence8
ICH-E6-DataMgmt-ExternalData-EHRs-RealWorldData-Coord-FDA-EMAICH E6 Data Management + External Data + EHR + Real-World Data + Coordination FDA + EMA + PMDA + ICH Family0
ICH-E6-EssentialDocs-TMF-eTMF-ArchiveRetention-ICH-Section8ICH E6 Section 8 - Essential Documents + Trial Master File (TMF) + eTMF + Archive + Retention9
ICH-E6-IRB-IEC-EthicsCommittee-InformedConsent-VulnerableICH E6 Section 3 - Institutional Review Board (IRB) + Independent Ethics Committee (IEC) + Informed Consent + Vulnerable Populations1
ICH-E6-Investigator-Qualifications-Resources-Communication-SafetyReportingICH E6 Section 4 - Investigator + Qualifications + Resources + Communication + Safety Reporting + Source Document Verification1
ICH-E6-Protocol-IB-CSR-ClinicalStudyReport-AuthoringICH E6 Section 6 + 7 - Protocol + Investigator Brochure (IB) + Clinical Study Report (CSR) + Reporting1
ICH-E6-Scope-Principles-R3-2025-Risk-Based-DecentralisedClinicalICH E6 Good Clinical Practice - Scope + 13 Principles + R3 January 2025 + Risk-Based + Decentralised + Modernisation81
ICH-E6-Sponsor-QualityRiskMgmt-Monitoring-CRO-VendorICH E6 Section 5 - Sponsor + Quality Management System + Risk-Based Monitoring + CRO + Vendor Oversight43
1.1-1.2IRB/IEC reviews the protocol, consent and assent materials, IB or product information, participant information, recruitment advertising, compensation plans, safety updates and inve0
1.3-1.5IRB/IEC has a qualified membership (recommended at least five, including a non-medical and an independent member) with only independent members voting, works to written procedures 0
2.1-2.2Investigators are qualified by education, training and experience, know the investigational product, can show realistic recruitment potential and have enough time, staff and facili0
2.10-2.11Manage investigational product at the site (accountability, storage, use per protocol, participant instruction, direct-to-participant delivery safeguards) under investigator oversi0
2.12-recordsMaintain and control the investigator's essential records per Appendix C, retain them for the required period or until the sponsor says they are no longer needed (whichever is long0
2.12-sourceEnsure integrity of site data: ALCOA-quality source records with traceable changes, a defined source and capture plan, timely review of data including external data, correct use of0
2.12-systemsFor site-deployed systems protect data from unauthorised access, alteration or loss, give secure attributable access, tell the sponsor of access changes for its systems, meet secti0
2.13On completion inform the institution, give the IRB/IEC a summary of the outcome and send regulators any required reports0
2.3Investigators delegate only to qualified, informed people and parties, keep a proportionate delegation record, document service provider agreements, retain responsibility and overs0
2.4Before starting, hold documented, dated IRB/IEC approval of the protocol, consent materials, recruitment procedures and participant information; supply the current IB, participant 0
2.5Sign the protocol or agreement, comply with the protocol, GCP and regulation, document every deviation, explain and prevent recurrence of important ones, deviate only to remove imm0
2.6On premature termination or suspension, inform participants promptly and ensure appropriate therapy and follow-up, and notify the institution, sponsor, IRB/IEC and regulators as th0
2.7Keep a qualified physician or dentist responsible for trial medical care, provide adequate care for trial-related adverse events, inform the primary physician with consent, report 0
2.8-contentCover every applicable consent element (purpose, research nature, product and randomisation, procedures, expectations, risks including to partners and pregnancy, benefits or none, 0
2.8-processRun the consent process to regulation, GCP and Helsinki principles: approved materials, clear simple information, suitable media with a paper option, remote consent where appropria0
2.9When participation ends early or routinely, follow the protocol including steps to retain collected data, try respectfully to learn the reason for withdrawal without undue influenc0
3.1Design trials with enough supporting safety and efficacy data, quality built in around critical to quality factors, input from interested parties and operational feasibility withou0
3.10Run a proportionate, risk-based quality management system with quality by design, identifying, evaluating, controlling (including pre-specified acceptable ranges such as quality to0
3.11-QAMaintain QA and QC processes and procedures; apply risk-based QA to find causes of serious noncompliance; and run independent, qualified, documented, risk-proportionate audits unde0
3.11-activitiesCarry out monitoring activities across the life cycle (communication and deviation follow-up, site selection to close-out checks, investigational product checks and data checks) an0
3.11-monitoringApply risk-based QC to data handling and monitor by independent, qualified people using a risk-based mix of site (on-site or remote) and centralised monitoring set out in a tailore0
3.12Act proportionately on noncompliance, perform root cause analysis and CAPA for significant noncompliance, notify regulators and IRB/IEC of serious noncompliance, and consider endin0
3.13Evaluate product safety continuously: aggregate and review safety information promptly, communicate relevant new information, submit safety updates and periodic reports, expedite S0
3.14Provide insurance or indemnity where required, address treatment costs for trial-related injury, and compensate participants as regulation requires0
3.15-info-mfgDevelop and update the IB (or identify basic product information), characterise and manufacture investigational products to GMP with blinding-protective coding and compliant labels0
3.15-supplySupply investigational product only after required approvals, with handling instructions, timely provision, records from shipment to disposition, retrieval and disposition processe0
3.16-dataHandle data with integrity and confidentiality: risk-focused QC, pre-specified data and collection methods, validated data tools, life-cycle processes, blinding safeguards and docu0
3.16-stats-recordsPre-specify analysis in a statistical analysis plan, control and trace programming and derivations, pre-define analysis set criteria, document and justify post-unblinding changes, 0
3.16-systemsKeep a record of important computerised systems (use, functionality, interfaces, validation status, responsibility, access controls and security), implement section 4 requirements,0
3.17On termination or suspension inform investigators, regulators and the IRB/IEC promptly with reasons and give follow-up information; prepare clinical trial reports to ICH E3; and af0
3.2-3.5Provide sufficient resources, allocate roles before trial activities begin, use qualified individuals including readily available medical expertise, and document financing in an ag0
3.6Document agreements with investigators, institutions, service providers and committees before activities start, secure their commitments to GCP, recording, retention and access, do0
3.7-3.8Select qualified, adequately resourced investigators (and document coordinating roles), give them the protocol and current IB with time to review, make required regulatory submissi0
3.9Oversee the trial so design, conduct, processes and data give reliable results and protect participants: classify important protocol deviations, assess decisions for impact, tailor0
4-blindingAddress the key data governance processes (confidentiality, computerised systems, safeguarding randomisation, dosing and blinding, supporting key decisions) and protect blinding th0
4.2-capture-reviewCover the data life cycle with procedures: risk-based verification of transcribed data, metadata with all captured data, controlled automated validation checks, metadata and audit 0
4.2-laterCorrect errors in an attributed, justified, source-supported and timely way; transfer and migrate data through validated or reconciled processes; finalise data sets for analysis un0
4.3-operationsRelease trial-specific systems to a site only after all its approvals, keep contingency procedures against data loss or inaccessibility, run help desk support with periodic review 0
4.3-use-securityDefine computerised system responsibilities, brief developers on purpose and requirements, involve intended users in design, document procedures for use, train users, and manage se0
4.3-validationOwn validation status across the life cycle with a risk-based approach that shows completeness, accuracy, reliability and consistent performance, validating before use, after risk-0
AEnsure an up-to-date Investigator's Brochure (or justified product information alternative) with reference safety information, reviewed at least annually, presented objectively and0
BWrite protocols and amendments containing the required content: general and background information, objectives, design, participant selection, discontinuation and withdrawal, treat0
CManage essential records: identify which are essential by risk and relevance, keep them identifiable, version controlled and approved, hold them in TMF and ISF repositories with a 0
P1Run trials ethically under Declaration of Helsinki principles, GCP and the law, with participants' rights, safety and well-being placed above science and society, timely safety rev0
P10Make roles and responsibilities clear and documented, keep overall responsibility when transferring or delegating activities, define them in agreements and oversee them0
P11Manufacture investigational products under applicable GMP, preserve their quality, use them per protocol, keep handling and labelling consistent with treatment assignment and blind0
P2Base participation on freely given, documented informed consent (or legally acceptable representative consent and minor assent) from a clear process suited to the trial, with defer0
P3Submit the trial to independent IRB/IEC review, conduct it under the approved protocol and undergo periodic IRB/IEC review0
P4Make trials scientifically sound, supported by adequate nonclinical and clinical data and current knowledge, and review new scientific information periodically for needed modificat0
P5Have trials designed and conducted by individuals qualified by education, training and experience for each task0
P6Build quality into trial design and conduct: treat quality as fitness for purpose, identify critical to quality factors prospectively, and prevent, detect and correct serious nonco0
P7Keep processes proportionate to risks to participants and the importance of the data, focus on risks beyond usual care, manage risks to critical factors proactively and avoid unnec0
P8Describe the trial in a clear, concise, scientifically sound and feasible protocol with explicit objectives and equally clear execution plans0
P9Generate reliable results through fit-for-purpose information, systems and validated computerised systems, robust record management, secure retention of essential records and trans0
introPurpose, scope and structure of ICH E6(R3)0

Tell me when ICH E6(R3) files something new

One email when a public company newly discloses something this framework governs, naming the company and what our corpus says it puts in scope. Nothing else, and one click to stop.

What this page is

A control-level reference for ICH E6(R3), drawn from our framework corpus. Control codes and titles are references to the standard, not reproductions of it. The overlap counts and the auditor artefacts are our own work and are the part you will not find elsewhere.

Measure this against what you already run · All frameworks · Today's edition